SEARCH

SEARCH BY CITATION

REFERENCES

  • Antonelli G, Giannelli G, Currenti M, Simeoni E, Del Vecchio S, Maggi F, Pistello M, Roffi L, Pastore G, Chemello L, Dianzani F. 1996. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy. Clin Exp Immunol 104: 384387.
  • Antonelli G, Simeoni E, Turriziani O, Tesoro R, Redaelli A, Roffi L, Antonelli L, Pistello M, Dianzani F. 1999. Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy. J Interferon Cytokine Res 19: 243251.
  • Asahina Y, Izumi N, Uchihara M, Noguchi O, Nishimura Y, Inoue K, Ueda K, Tsuchiya K, Hamano K, Itakura J, Miyake S. 2003. Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens. J Hepatol 39: 421427.
  • Bendtzen K. 2003. Anti-IFN BAb and NAb antibodies: A minireview. Neurology 61: S6S10.
  • Bonetti P, Diodati G, Drago C, Casarin C, Scaccabarozzi S, Realdi G, Ruol A, Alberti A. 1994. Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha. J Hepatol 20: 416420.
  • Bonino F, Baldi M, Negro F, Oliveri F, Colombatto P, Bellati G, Brunetto M. 1997. Clinical relevance of anti-interferon antibodies in the serum of chronic hepatitis C patients treated with interferon-alpha. J Interferon Cytokine Res 17: S3538.
  • Boyum A. 1968. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 97: 7789.
  • Canosi U, Mascia M, Gazza L, Serlupi-Crescenzi O, Donini S, Antonetti F, Galli G. 1996. A highly precise reporter gene bioassay for type I interferon. J Immunol Methods 199: 6976.
  • Chieux V, Hober D, Harvey J, Lion G, Lucidarme D, Forzy G, Duhamel M, Cousin J, Ducoulombier H, Wattré P. 1998. The MxA protein levels in whole blood lysates of patients with various viral infections. J Virol Methods 70: 183191.
  • Craxi A, DiMarco V, Volpes R, Palazzo U. 1988. Anti-alpha interferon antibodies after alpha interferon treatment in patients with chronic viral hepatitis. Hepatogastroenterology 35: 304305.
  • Der SD, Zhou A, Williams BR, Silverman RH. 1998. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 95: 1562315628.
  • Di Bisceglie A, Conjeevaram H, Fried M, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner D, Mahaney K, Hoofnagle J. 1995. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123: 897903.
  • Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, Fryden A, Reesink H, Bassendine M, Norkrans G, Cuypers T, Lelie N, Telfer P, Watson J, Weegink C, Sillikens P, Weiland O. 1996. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study. J Hepatol 25: 591598.
  • Fernandez M, Quiroga J, Martin J, Herrero M, Pardo M, Horisberger M, Carreno V. 1999. In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus. J Infect Dis 180: 262267.
  • Flohr F, Schneider-Schaulies S, Haller O, Kochs G. 1999. The central interactive region of human MxA GTPase is involved in GTPase activation and interaction with viral target structures. FEBS Lett 463: 2428.
  • Frese M, Pietschmann T, Moradpour D, Haller O, Bartenschlager R. 2001. Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J Gen Virol 82: 723733.
  • Giannelli G, Antonelli G, Fera G, Del Vecchio S, Riva E, Broccia C, Schiraldi O, Dianzani F. 1994. Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C. Clin Exp Immunol 97: 49.
  • Hagmaier K, Jennings S, Buse J, Weber F, Kochs G. 2003. Novel gene product of thogoto virus segment 6 codes for an interferon antagonist. J Virol 77: 27472752.
  • Haller O, Kochs G. 2002. Interferon-induced Mx proteins: Dynamin-like GTPases with antiviral activity. Traffic 3: 710717.
  • Hoofnagle J, Lau D, Conjeevaram H, Kleiner D, Di Bisceglie A. 1996. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepat 3: 247252.
  • Hou C, Chuang W, Yu M, Dai C, Chen S, Lin Z, Hsieh M, Wang L, Tsai J, Chang W. 2000. Incidence and associated factors of neutralizing anti-interferon antibodies among chronic hepatitis C patients treated with interferon in Taiwan. Scand J Gastroenterol 35: 12881293.
  • Hug H, Costas M, Staeheli P, Aebi M, Weissmann C. 1988. Organization of the murine Mx gene and characterization of its interferon- and virus-inducible promoter. Mol Cell Biol 8: 30653079.
  • Jakschies D, Zachoval R, Muller R, Manns M, Nolte K, Hochkeppel H, Horisberger M, Deicher H, Von Wussow P. 1994. Strong transient expression of the type I interferon-induced MxA protein in hepatitis A but not in acute hepatitis B and C. Hepatology 19: 857865.
  • Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4: 6977.
  • Leroy V, Baud M, de Traversay C, Maynard-Muet M, Lebon P, Zarski J. 1998. Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C. J Hepatol 28: 375381.
  • Lleonart R, Naf D, Browning H, Weissmann C. 1990. A novel, quantitative bioassay for type I interferon using a recombinant indicator cell line. Biotechnology (N Y) 8: 12631267.
  • Meier V, Mihm S, Ramadori G. 2000. MxA gene expression in peripheral blood mononuclear cells from patients infected chronically with hepatitis C virus treated with interferon-alpha. J Med Virol 62: 318326.
  • Milella M, Antonelli G, Santantonio T, Currenti M, Monno L, Mariano N, Angarano G, Dianzani F, Pastore G. 1993. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver 13: 146150.
  • Milella M, Antonelli G, Santantonio T, Giannelli G, Currenti M, Monno L, Turriziani O, Pastore G, Dianzani F. 1995. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN. Hepatogastroenterology 42: 201204.
  • Pachner A, Bertolotto A, Deisenhammer F. 2003. Measurement of MxA mRNA or protein as a marker of IFNb bioactivity. Neurology 61: S24S26.
  • Poynard T, Yuen M, Ratziu V, Lai C. 2003. Viral hepatitis C. Lancet 362: 20952100.
  • Roers A, Hochkeppel H, Horisberger M, Hovanessian A, Haller O. 1994. MxA gene expression after live virus vaccination: A sensitive marker for endogenous type I interferon. J Infect Dis 169: 807813.
  • Roffi L, Mels G, Antonelli G, Bellati G, Panizzuti F, Piperno A, Pozzi M, Ravizza D, Angeli G, Dianzani F, et al. 1995. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: Prevalence, etiology, and management. Hepatology 21: 645649.
  • Ronnblom L, Janson E, Perers A, Oberg K, Alm G. 1992. Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment. Clin Exp Immunol 89: 330335.
  • Ross C, Engler C, Sander B, Bendtzen K. 2002. IFN-a antibodies in patients with age-related macular degeneration treated with recombinant human IFN-a2a. J Interferon Cytokine Res 22: 421426.
  • Scagnolari C, Casato M, Bellomi F, DePisa F, Turriziani O, Coviello R, Pirro M, Dianzani F, Antonelli G. 2003. Serum interferon (IFN)-neutralizing antibodies and bioactivity of IFNs in patients with severe type II essential mixed cryoglobulinemia. Clin Diagn Lab Immunol 10: 7077.
  • Shiffman M, Di Bisceglie A, Lindsay K, Morishima C, Wright E, Everson G, Lok A, Morgan T, Bonkovsky H, Lee W, Dienstag J, Ghany M, Goodman Z, Everhart J. 2004. Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126: 10151023.
  • Sorensen P, Ross C, Clemmesen K, Bendtzen K, Frederiksen J, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N. 2003. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362: 11841191.
  • Steis R, Smith J, Urba W, Clark J, Itri L, Evans L, Schoenberger C, Longo D. 1988. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 318: 14091413.
  • Von Wussow P, Freund M, Block B, Diedrich H, Poliwoda H, Deicher H. 1987. Clinical significance of anti-IFN-a antibody titres during interferon therapy. Lancet 2: 635636.